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Normal thyroid function tests and fracture risk 
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Context 
Hyperthyroidism is associated with increased fracture risk, but it is not clear if lower TSH and 
higher free thyroxine (FT4) in euthyroid individuals are associated with fracture risk.  
Objective 
To evaluate the association of TSH and FT4 with incident fractures in euthyroid individuals.  
Design 
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Individual participant data analysis. 
Setting 
Thirteen prospective cohort studies with baseline examinations between 1981 and 2002. 
Participants 
Adults with baseline TSH 0.45-4.49 mIU/L. 
Main Outcome Measures 
Primary outcome was incident hip fracture. Secondary outcomes were any, non-vertebral, and 
vertebral fractures. Results were presented as hazard ratios (HR) with 95% confidence interval 
(CI) adjusted for age and sex. For clinical relevance, we studied TSH according to five 
categories: 0.45-0.99mIU/L; 1.00-1.49mIU/L; 1.50-2.49mIU/L; 2.50-3.49mIU/L; 3.50-
4.49mIU/L (reference). FT4 was assessed as study-specific standard deviation increase, because 
assays varied between cohorts. 
Results 
During 659,059 person-years, 2,565/56,835 participants had hip fracture (4.5%; 12 studies with 
data on hip fracture). The pooled adjusted HR (95% CI) for hip fracture was 1.25 (1.05-1.49) for 
TSH 0.45-0.99mIU/L, 1.19 (1.01-1.41) for TSH 1.00-1.49mIU/L, 1.09 (0.93-1.28) for TSH 1.50-
2.49mIU/L, and 1.12 (0.94-1.33) for TSH 2.50-3.49mIU/L (P for trend = 0.004). Hip fracture 
was also associated with FT4 (HR [95%CI] 1.22 [1.11-1.35] per one standard deviation increase 
in FT4). FT4 only was associated with any and non-vertebral fracture. Results remained similar 
in sensitivity analyses. 
Conclusions  
Among euthyroid adults, lower TSH and higher FT4 are associated with an increased risk of hip 
fracture. These findings may help refine the definition of optimal ranges of thyroid function tests.  
In an individual participant data analysis of 13 prospective cohorts, lower thyroid-stimulating hormone 
within reference range and higher FT4 were associated with an increased hip fractures risk. 
INTRODUCTION 
Overt hyperthyroidism is a well-known risk factor for fracture and is associated with decreased 
bone mineral density (BMD) (1). We recently showed that subclinical hyperthyroidism was also 
associated with increased fracture incidence (2). Thyroid hormones stimulate bone turnover 
acting directly and indirectly on osteoclasts and osteoblasts (3). Anabolic action is net during 
growth, but in adults, catabolic action leads to greater bone loss and higher fracture risk (3). 
Thyroid hormones might also decrease muscular strength and coordination, and increase the risk 
of fall (4, 5). Administering TSH reduces bone resorption and increases bone formation in post-
menopausal women monitored for thyroid cancer (6). Conversely, high TSH levels can degrade 
bone quality by increasing cortical, rather than trabecular bone.  
The reference range for thyroid function tests – “euthyroidism” – is defined by the 2.5 to 97.5 
percentiles in an apparently healthy population. However, the studies from which TSH reference 
range was derived did not exclude participants with occult or underlying disease, e.g. those with 
positive anti-thyroid antibodies, which might bias the reference range towards higher TSH values 
(7, 8). In medicine, reference ranges can be derived from normative data, as for thyroid function 
tests, or preferably determining levels associated with important risks or outcomes, as for lipids, 
or blood pressure. 
TSH within the lower reference range has been associated with osteoporosis and fracture 
mostly in cross-sectional studies of healthy post-menopausal women, but prospective data are 
limited and conflicting (5, 9-13). If we can better understand the association between TSH and 
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health outcomes, we could make more accurate estimates of fracture risk, which would help 
refine thyroxine treatment targets. We hypothesized that lower TSH and higher FT4 in euthyroid 
participants were associated with increased risk of fractures. We therefore aimed to assess the 
association between TSH within the reference range, free thyroxine (FT4), and fracture risk by 
analyzing individual participant data (IPD) of population-based prospective cohort studies 
participating to the international Thyroid Studies Collaboration (2, 14).  
METHODS 
Data source, searches and study selection  
The study protocol was registered on PROSPERO prior to study conduct (available on 
http://www.crd.york.ac.uk/PROSPERO; registration number: CRD42016039125). 
We updated our previous systematic literature search, which had identified in Ovid 
(MEDLINE) and EMBASE from inception to March 2015 all prospective cohorts of adults with 
baseline TSH and FT4 measurement and follow-up evaluation for incident fracture (2). 
Additionally, we searched for studies with participants with only euthyroidism, which may have 
been omitted in our initial search. Our Ovid (MEDLINE) and EMBASE search (until 
05/19/2016) used following medical search terms: euthyroid, euthyroidism or normal TSH and 
fractures or osteoporosis. After retrieving studies according to titles and abstracts, two authors 
(C.E.A. and D.S.) independently reviewed full-texts to confirm study eligibility. Disagreements 
were resolved by consensus with a third author (N.R.). We also requested unpublished fracture 
data from all cohorts of the Thyroid Studies Collaboration (2, 14-17). Exclusion criteria were: 1) 
cohorts using first-generation TSH assays because these assays were not sensitive enough; 2) 
studies with only participants aged <18 years; 3) studies with only participants with thyroid 
medication (thyroxine or anti-thyroid drugs); 4) studies with only participants with TSH outside 
the reference range (<0.45mIU/L or >4.49mIU/L); and, 5) studies exclusively on participants 
after thyroid surgery. Agreement between reviewers was 100% (K =1.00). For the IPD analysis, 
we included all participants aged ≥18 years at enrollment with measured TSH at baseline 
evaluation, and fracture assessment, as defined below, at follow-up. 
Data extraction and quality assessment 
If the cohorts identified met our eligibility criteria, they were invited to provide IPD. Each study 
was approved by its local ethics committee. All participants gave informed consent for the 
original studies. We collected information on demographics, anthropometrics, medications, other 
risk factors for fracture, history of thyroid disorders, BMD and incident fracture. 
Risk of bias and study quality were independently assessed by C.E.A and D.S., using the 
following Newcastle-Ottawa Quality Assessment Scale items (18): 1) cohorts selection; 2) 
cohorts representativeness; 3) ascertainment of exposure; 4) availability of relevant confounding 
factors for adjustment; 5) outcome assessment based on objective fracture assessment, with 
adjudication procedure for fractures other than hip; 6) length of follow-up; 7) adequacy of 
follow-up; 8) researchers/participants/physicians blinding to thyroid values; and, 9) publication 
status. In sensitivity analyses, we excluded cohorts that did not meet one or more item(s). 
Data synthesis and analysis 
Definition of thyroid function 
All included studies used a third-generation TSH radioimmunoassay. Details on the assays used 
for TSH and FT4 measurement are described in Supplemental Table 1. To maximize 
comparability, we used uniform TSH thresholds based on previously established thresholds, as 
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done in previous reports of the Thyroid Studies Collaboration (2, 14). We defined euthyroidism 
as TSH 0.45-4.49mIU/L. For clinical relevance, we separated TSH values into five categories: 
0.45-0.99mIU/L; 1.00-1.49mIU/L; 1.50-2.49mIU/L; 2.50-3.49mIU/L; 3.50-4.49mIU/L. The later 
was used as reference category because we hypothesized, based on our previous publication (2), 
that lower TSH might be associated with higher fracture risk.  Because of different FT4 reference 
ranges across studies, we used standard deviation (SD) rather than specific cut-offs. FT4 was 
available for all but two studies in the euthyroid range (19, 20). 
Definition of outcomes 
Our primary outcome was incident hip fracture, including femoral neck, pertrochanteric, and 
subtrochanteric fractures, as previously defined (2). Briefly, we excluded pathologic (i.e. 
associated with metastasis or rare bone disease) and periprosthetic fractures. Any, non-vertebral 
and clinical vertebral incident fractures were secondary outcomes. We excluded 1) vertebral 
fractures diagnosed with only radiologic imaging to keep focus on clinical relevance; 2) cervical 
and sacral vertebral fractures because fractures at these locations are usually associated with 
trauma rather than osteoporosis. “Any fractures” included fractures at any location, except for 
skull, face, ankle, finger, or toe, since these are not related to osteoporosis. “Non-vertebral 
fractures” was the same as “any fractures” except it excluded vertebral fractures. For any and 
non-vertebral fractures, we excluded cohorts that collected fracture data on only part of the 
skeleton. Supplemental Table 2 describes fracture definitions by study. 
Statistical analyses 
We used a shared frailty Cox regression model with random-effects at study level to conduct an 
IPD meta-analysis, which used data from all included cohorts to assess the relationship of 
incident fractures with TSH categories and FT4, respectively (21, 22).  The random-effects 
accounted for the between-study variation caused by different definitions of TSH reference range 
across the studies, incorporating the extra uncertainty in the confidence intervals. We used 
Schoenfeld residuals to test the proportional-hazards assumption (23). Results were presented as 
hazard ratios (HR) compared to the reference category. Time-to-event was defined for each 
outcome from baseline TSH measurement to first fracture event. We adjusted primary analyses 
for age and sex, and then for other risk factors for fracture (body mass index [BMI], smoking, 
and history of diabetes), because they might mediate the association between thyroid function 
tests and fractures. We conducted following predefined sensitivity analyses: 1) excluding 
participants with thyroid medication (thyroxine or anti-thyroid medication) at baseline; 2) 
excluding participants with thyroid-altering medication at baseline (thyroid medication, oral 
corticosteroids, amiodarone, iodine); 3) excluding participants with anti-fracture medication at 
baseline (bisphosphonate, calcitonin, selective estrogen receptor modulator, parathyroid 
hormone); 4) including only studies with formal fracture adjudication; 5) including only studies 
that uniformly defined fractures (except for hip fracture, since it has a common definition and is 
rarely reported in error); 6) excluding cohorts with loss to follow-up rates >5%; 7) excluding 
participants who developed overt or subclinical thyroid dysfunction over time; 8) including only 
participants with TSH remaining within the reference range during follow-up; and 9) further 
adjusting for BMD, which reflects bone loss and may be a potential mediator between TSH or 
FT4 and incident fractures. In this last analysis, we used BMD as a continuous variable, and 
included only studies that used dual energy X-ray absorptiometry (DXA) devices with femoral 
neck BMD for hip fractures (available for six studies) (5, 10, 14, 24-26), lumbar spine BMD for 
vertebral fractures (available for one study) (10), and whole body BMD for any fractures 
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(available for one study) (10) . We conducted predefined stratified analyses by sex, age (<75 
versus ≥75 years), and duration of follow-up (<5 versus ≥5 years).  
For the FT4 analysis, we used the whole range of FT4 values including only participants with 
TSH within the reference range. FT4 values were converted to ng/mL (12.87pmol/L = 1ng/mL). 
We used study-specific SD to assess fracture risk per one SD increase in FT4 because FT4 
assays varied between cohorts (14). We performed the same sensitivity and stratified analyses as 
for TSH.  
We used STATA release 13.1 for all analyses (StataCorp LP, College Station, Texas). All 
tests were two-sided, at a 0.05 level of significance. 
RESULTS 
Our updated literature search identified nine additional reports (Supplemental Figure 1) (2). 
Eight of them concerned studies already identified in our previous search (2). The newly 
identified study (Study of Osteoporotic Fractures) (19) agreed to participate.  We excluded the 
Nagasaki Adult Health Study (27), because it used first-generation TSH assays, which have a 
low functional sensitivity (1mIU/L) (28). For the same reason, this study had been included in 
our previous work (2) only in the analysis on subclinical hypothyroidism, but not on subclinical 
hyperthyroidism (16).  We included thirteen studies (5, 10, 14, 17, 19, 25, 26, 29-34) from the 
USA, Europe, and Australia with 61,959 participants, and a median duration of follow-up of 12.1 
years (interquartile range [IQR] 8.5-12.9), totaling 659,059 person-years. Median age was 64 
(range 18-102) with 60.5% women (Table 1). Median (IQR) TSH was 1.60mIU/L (1.10-2.30); 
3.1% of participants used thyroid medication at baseline and 5.5% during follow-up; 17.7% had 
a TSH 0.45-0.99mIU/L, 24.8% 1.00-1.49mIU/L, 37.4% 1.50-2.49mIU/L, 14.2% 2.50-
3.49mIU/L and 5.9% 3.50-4.49mIU/L. Hip fracture occurred in 2,565 participants (4.5%; 12 
studies), any fracture in 2,333 (8.9%; 9 studies), non-vertebral fracture in 1,874 (8.5%; 9 
studies), and vertebral fracture in 263 (1.3%; 7 studies). Overall quality was good 
(Supplemental Table 3):  one study reported loss to follow-up >5% (5), four did not perform 
formal fracture adjudication (25, 29, 32, 33), and three had not published fracture data in a 
separate manuscript (17, 29, 33).  
Tests of the proportional-hazards assumption on the basis of Schoenfeld residuals indicated 
that assumptions were met for all analyses (P > 0.11 for all). 
Thyroid function and hip fractures 
Compared with the reference group (TSH 3.50-4.49mIU/L), pooled age- and sex-adjusted HR 
(95% CI) for hip fracture was 1.25 (1.05-1.49) for TSH 0.45-0.99mIU/L, 1.19 (1.01-1.41) for 
TSH 1.00-1.49mIU/L, 1.09 (0.93-1.28) for TSH 1.50-2.49mIU/L, and 1.12 (0.94-1.33) for TSH 
2.50-3.49mIU/L (P for trend 0.004, Figure 1). After adjusting for BMI, smoking status, and 
history of diabetes, HR (95% CI) was 1.24 (1.03-1.49) for TSH 0.45-0.99mIU/L compared with 
the reference group, while HR (95%CI) for TSH 1.00-1.49mIU/L was somewhat attenuated and 
no longer statistically significant (1.15 [0.97-1.38]). The risk of hip fracture in participants with 
TSH 0.45-0.99mIU/L remained significantly higher in all sensitivity analyses, and was even 
higher after adjusting for femoral neck BMD (Table 2). For TSH 1.00-1.49mIU/L, the risk of 
hip fractures remained significantly higher in all sensitivity analyses, except after adjusting for 
femoral neck BMD, or after excluding participants with thyroid-altering medication at baseline. 
This association remained not significant for TSH 1.50-2.49mIU/L, or TSH 2.50-3.49mIU/L. We 
found no significant interaction for sex, age, or duration of follow-up (Supplemental Figure 2), 
although confidence intervals were larger and point estimates smaller for age <75 years and 
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follow-up <5 years. Conversely, there was significant interaction for publication status with a 
HR (95% CI) of 1.35 (1.13-1.61) for the ten studies that published risk of hip fracture associated 
with thyroid function tests in a separate manuscript, and 0.44 (0.21-0.90) for the two studies (17, 
29) that did not previously publish hip fracture data associated with thyroid function tests in a 
separate article (P for interaction 0.0001, Supplemental Table 4). 
The HR (95% CI) for hip fracture was 1.24 (1.12-1.37) per one SD increase in FT4 (Figure 
2). We found no significant interaction with sex, age, duration of follow-up, or publication status 
of hip fracture data (Figure 2, Supplemental Table 4), although point estimate was smaller 
when follow-up was <5 years. All sensitivity analyses yielded similar results (Table 2). In the 
25,760 participants of the five cohorts with available data on thyroid function tests during 
follow-up (25, 29, 31-33), 146 (0.6%) participants developed subclinical hyperthyroidism and 46 
(0.2%) overt hyperthyroidism. When we included only endogenous forms of thyroid dysfunction 
(i.e., participants without thyroxine use at baseline, N=25,049), 102 (0.4%) and 25 (0.1%) 
participants developed subclinical and overt hyperthyroidism, respectively. The HR (95% CI) for 
hip fracture for TSH 0.45-0.99mIU/L compared with the reference group was 1.70 (1.13-2.57) in 
the sensitivity analysis including only participants with TSH remaining within the reference 
range (four cohorts with data on hip fracture and thyroid function tests during follow-up) (25, 29, 
31, 32). 
Thyroid function and any, non-vertebral, and vertebral fractures 
For all TSH categories when compared with the reference group, we found no significant 
association for any, non-vertebral, or vertebral fractures (Supplemental Table 5). The HR (95% 
CI) per one SD increase in FT4 was 1.08 (1.02-1.15) for any fracture, and 1.10 (1.03-1.18) for 
non-vertebral fracture. These associations remained significant in most sensitivity analyses 
(Table 3), except when adjusting for BMD. Association between FT4 and vertebral fracture was 
not statistically significant, possibly because of the lower number of data (Table 3). We found 
no significant interaction in the analyses stratified by sex, age, duration of follow-up, or 
publication status for any of these fracture outcomes (Table 3, Supplemental Table 4).  
DISCUSSION 
In this analysis of 61,959 euthyroid participants of thirteen prospective cohorts with 659,059 
person-years of follow-up, lower TSH levels within the reference range were associated with 
increased risk of hip fracture, and higher FT4 levels with increased risk of hip, any, and non-
vertebral fracture. 
While overt and subclinical hyperthyroidism have been associated with increased fracture 
risk (1, 2), previous studies on the relationship between TSH within the reference range and 
fracture risk had conflicting results. The Clalit Health Services, a large historical cohort study, 
found a borderline increased incidence of hip fracture with TSH 0.35-1.6mIU/L when compared 
with TSH 1.7-2.9mIU/L, but in women only (odds ratio [95%CI] 1.28 [1.03-1.59]), while the 
association with other osteoporotic fractures was not statistically significant (11). A small cross-
sectional study (N=129) found an association between low TSH and vertebral fracture (12). The 
Cardiovascular Health Study found no significant association between TSH within the reference 
range or FT4 assessed as continuous variables and hip fracture (13), but, consistent with our 
findings, curves bent with an increased fracture risk for TSH <1.5mIU/L and for FT4 
>1.4ng/mL. Our thorough IPD analysis across multiple prospective cohorts confirms the 
association between low TSH and hip fractures, and an association between high FT4 and all but 
vertebral fractures in participants with TSH within the reference range, suggesting that even a 
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modest increase in thyroid hormone levels among euthyroid adults is associated with higher 
fracture risk. 
Our study was strengthened, first, by an IPD analysis that allowed us to standardize the 
definitions of predictors and outcomes, adjust for similar potential confounders, and avoid 
aggregation bias for subgroup analyses. This was the best way to perform time-to-event analysis. 
Second, our study is the largest to assess fracture risk in prospective cohorts with TSH within the 
reference range. Third, we included all international prospective cohorts available on this topic, 
since all the studies we identified agreed to participate.  
Our study had several limitations. First, our population consisted mostly of Caucasians and 
included few young adults. Second, thyroid function tests were performed only at baseline in 
most cohorts, so we may have included adults who later developed subclinical or overt thyroid 
dysfunction. However, our sensitivity analysis including only participants with persistent TSH 
within the reference range yielded an even stronger association between low TSH and hip 
fracture. In addition, other participants may have had a non-thyroidal illness, a potential cause of 
suppressed TSH; however, the prevalence of non-thyroidal illness was likely low as we only 
studied community-dwelling adults. Third, fractures were adjudicated in nine of thirteen cohorts, 
and we could not uniformly define each fracture type across all cohorts. Nevertheless, sensitivity 
analyses limited to cohorts with the most uniform facture definitions or adjudicated fracture 
yielded similar results. Fourth, we did not know fracture mechanism, but we excluded 
pathological fractures and fracture locations typically not associated with osteoporosis to reduce 
bias related to traumatic fractures. Fifth, data on fractures other than hip location were available 
in a more limited number of studies, reducing the number of outcomes and the related power to 
identify associations. Sixth, we had no information on other factors that may have influenced 
bone integrity or accounted for variations in circulating TSH or FT4, such as nutrition or 
deiodinase activities. Finally, thyroid antibodies were not systematically measured and their 
potential impact on bone metabolism could not be assessed. 
Our findings may have two important clinical implications. First, TSH reference range is still 
a matter of debate (35). TSH reference range was indeed defined in a population that included 
persons with occult or underlying thyroid disease (7, 8). TSH between 0.4 and 2.5mIU/L is 
associated with a lower incidence of thyroid dysfunction (36), but previous studies showed 
various adverse outcomes associated with subclinical thyroid dysfunction (14-16), and with TSH 
at both extremities of the reference range (e.g. higher risk of cardiovascular disease with high 
TSH/low FT4, and higher risk of fractures, osteoporosis, and dementia with low TSH/high FT4) 
(9, 13). There may be optimal values of thyroid function tests within the reference range. 
Second, similar to previous studies showing stronger association of adverse outcomes with 
FT4 than TSH (37, 38), FT4 was associated with hip, any and non-vertebral fracture, while TSH 
was associated only with hip fracture. TSH and thyroid hormones may act differently on 
peripheral organs, including bones: TSH may act on osteoblasts and osteoclasts via specific 
receptors (3), while thyroid hormones may act on target tissues via nuclear receptors controlled 
locally by deiodinases (3, 39, 40). This may explain why TSH and FT4 are associated with 
different fracture types. FT4 may therefore help evaluate osteoporosis and fracture risk, which is 
now usually done with the World Health Organization FRAX score, but future studies should 
determine if adding FT4 improves clinical accuracy of this score. Of note, FT4 was not 
significantly associated with vertebral fracture. One explanation may be that FT4 acts differently 
on vertebral bone. It may however also be due to lack of power, as we could include about ten 
times fewer vertebral than other fractures (Table 3). 
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We may have expected a stronger association of fracture risk with TSH and FT4, 
respectively, after excluding participants with thyroid medication at baseline, but the risk was 
only slightly increased, probably because of the low number of participants with thyroid 
medication at baseline (N=1897, 3%). 
In conclusion, analyzing individual data of 61,959 adults from thirteen large prospective 
cohorts, we found that TSH at the lower extremity of the reference range was associated with 
higher risk of hip fractures, and high FT4 with higher risk of hip, any, and non-vertebral 
fractures. Our findings may help refine the current definition of optimal thyroid function. 
Meanwhile, clinicians should be aware that lower TSH and higher FT4, even within the 
reference range, are associated with an increased risk of hip fracture.  
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Figure 1. Title: Risk of hip fracture according to thyroid-stimulating hormone categories. 
Legend: Abbreviations: CI, confidence interval; HR; hazard ratio; No., number; TSH, thyroid-
stimulating hormone. Data on hip fractures were available for 12 studies (all except PROSPER). 
Figure 2. Title: Risk of hip fracture per one standard deviation increase in free thyroxine, 
overall and stratified by sex, age, and duration of follow-up. Legend: Abbreviations: CI, 
confidence interval; FT4, free thyroxine; Health ABC, Health, Aging and Body Composition; 
HR; hazard ratio; No., Number; SOF, Study of Osteoporotic fractures, TSH, thyroid-stimulating 
hormone. The analysis stratified for sex was adjusted for age. All other analyses were adjusted 
for age (as a continuous variable) and sex. FT4 was measured in all studies but SOF and Health 
ABC Study (FT4 not measured in participants with TSH within the reference range). Data on hip 
fractures were available for 10 studies with measured FT4 (all except PROSPER). 
Table 1. Study population and baseline characteristics of the participants in the 13 included 
studies (n=61,959) 
Study name,  
place 
Description 
of  study 
population 
Numbe
r of 
particip
ants 
Age, 
median 
(range)* 
Women,  
No. (%) 
TSH, 
media
n, 
mIU/
L 
Thyroid 
medicatio
n at 
baseline, 
No. 
(%)†,‡ 
Thyroid 
medication 
during 
follow-up, 
No. 
(%)†,§ 
Start of 
follow-up, 
year 
Duration of 
follow-up,  
median 
(IQR), years|| 
Person-
years 
Busselton Health 
Study, Australia 
(29)  
Adults 1,907 51  (18-90) 919 (48.2) 1.42 10 (0.5) 15 (0.8) 1981 
20.0 (17.6-
20.0) 33,281 
CHS, USA (4 
communities) (25)  
Adults with 
Medicare 
eligibility 
2,853 71  (65-100) 
1,694 
(59.4) 2.03 145 (5.1) 299 (10.5) 1989-1990 
12.9 (7.5-
18.9) 36,466 
EPIC-Norfolk 
Study, England 
(30)  
Adults aged  
45-79y 11,986 
58  (40-
78) 
6,365 
(53.1) 1.70 275 (2.3) NA 1995-1998 
12.4 (11.7-
13.3) 142,951 
Health ABC 
Study, USA (4 
communities) (14)  
Adults aged  
70-79y with 
Medicare 
eligibility 
2,347 74  (69-81) 
1,165 
(49.6) 1.99 177 (7.5) 383 (13.9) 1997 
12.7 (8.1-
13.2) 24,794 
HUNT Study, 
Norway (31) ¶ Adults 31,388 
57  (19-
99) 
21,186 
(67.5) 1.60 999 (3.2) NA 1995-1997 
12.2 (11.6-
12.8) 345,517 
InCHIANTI 
Study, Italy (17)   
Adults aged 
≥65y 1,066 
71  (21-
102) 590 (55.3) 1.38  17 (1.6) 28 (2.6) 1998 9.1 (7.8-9.3) 8,562 
Leiden 85-Plus 
Study, The 
Netherlands (32) 
Adults aged 
85y 456 
85  (85-
85) 293 (64.3) 1.66 6 (1.3) 11 (2.4) 1997-1999 4.8 (2.2-8.1) 2,411 
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14 
MrOS, USA (6 
clinical centers) 
(10) 
Men aged 
≥65y 1,410 
73  (65-
99) All men 1.97 83 (5.9) 98 (6.9) 2000-2002 
11.1 (8.1-
11.8) 13,568 
OPUS, Germany, 
France, UK (5)** 
Women aged  
20-80y 1,205 
63  (20-
80) All women 0.96 0 (0.0) NA 1999-2001 6.0 (5.8-6.3) 7,179 
PROSPER, 
Ireland, Scotland, 
The Netherlands 
(33) 
Older adults 
at high 
cardiovascular 
risk 
5,124 75  (69-83) 
2,527 
(49.3) 1.75 135 (2.6) 163 (3.2) 1997-1999 3.2 (3.0-3.5) 15,833 
Rotterdam Study, 
The Netherlands 
(34) 
Adults aged 
≥55y 1,611 
68  (55-
93) 957 (59.4) 1.54 21 (1.3) NA 1989-1992 
15.2 (10.4-
16.2) 21,130 
Sheffield Study, 
England (26)  
Women aged  
50-85y 291 
63  (50-
86) All women 2.00 2 (0.7) 9 (3.1) 1990-1991 
10.0 (5.5-
10.1) 2,301 
SOF, USA (4 
clinical centers) 
(19)†† 
Women >65y 314 71  (65-88) All women 1.50 15 (4.8) NA 1986-1998 
14.3 (9.8-
19.8) 4,433 
Overall 13 cohorts 61,959 64  (18-102) 
37,506 
(60.5) 1.60 
1,885 
(3.1) 831 (5.5) 1981-2002 
12.1  (8.5-
12.9) 659,059 ‡‡ 
Abbreviations: CHS, Cardiovascular Health Study; EPIC, European Prospective Investigation of Cancer; Health 
ABC, Health, Aging and Body Composition; HUNT, Nord-Trøndelag Health Study; InCHIANTI, Invecchiare in 
Chianti; IQR, interquartile range; MrOS, Osteoporotic Fractures in Men Study; No., number; OPUS, Osteoporosis 
and Ultrasound Study; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; SOF, Study of 
Osteoporotic Fractures; TSH, thyroid-stimulating hormone; UK, United Kingdom; USA, United States of America; 
y, years.  
* We excluded participants younger than 18y. 
† Thyroid medication was defined as thyroxine or anti-thyroid medication. 
‡ Data on thyroid medication at baseline was missing for 255 participants in the HUNT Study, 59 participants in the 
MrOS, one participant in the Rotterdam Study, four participants in the SOF and seven participants in the Health 
ABC Study. 
§ Data on thyroid mediation at follow-up was missing for 243 participants in the MrOS, 96 participants in the 
InCHIANTI Study, 45 participants in the Sheffield Study, and all participants in the HUNT Study, EPIC-Norfolk 
Study, Rotterdam Study, OPUS and SOF. 
||
 Duration of follow-up was defined as the maximum duration of follow-up that was available, i.e. the time to the 
first hip (or any if unavailable) fracture or censor date/death. 
¶ We included participants excluded from the original article of the HUNT Study (participants <40y, with previous 
fracture and/or with previous thyroid disease), which explains the different number of the sample. 
**
 We included only the thyroid hormone sub-study of the OPUS, which excluded participants on thyroid 
medication. 
†† We included only a subsample of the SOF, i.e., the participants with TSH measurement at baseline. 
‡‡ It was calculated as time to hip fracture; for the PROSPER, it was calculated as time to any fracture, since data 
on hip fracture was unavailable. 
Table 2: Sensitivity analyses for the risk of hip fracture according to thyroid-stimulating 
hormone and free thyroxine  
Analysis by TSH category* Analysis by SD increase in FT4†  
No. of events/ 
participants 
Hazard ratio (95% 
CI)‡ 
No. of events/ 
participants 
Hazard ratio (95% 
CI)§ 
Main analysis 610/13,390 1.25 (1.05-1.49) 542/20,633 1.24 (1.12-1.37) 
  Medication use 
 Excluding participants with thyroid medication at baseline|| 557/12,728 1.28 (1.06-1.53) 526/20,158 1.26 (1.13-1.40) 
 Excluding participants with thyroid-altering medication at 
baseline¶ 
542/12,396 1.28 (1.07-1.55) 506/19,679 1.26 (1.13-1.40) 
 Excluding participants with anti-fracture medication at baseline** 605/12,739 1.27 (1.07-1.52) 539/20,563 1.24 (1.12-1.38) 
  Definition of fracture 
  Including only studies with formal fracture adjudication†† 496/12,048 1.31 (1.06-1.60) 416/17,913 1.21 (1.07-1.36) 
  Other  
  Excluding one study with loss to follow-up >5%‡‡ 606/12,748 1.26 (1.05-1.50) 536/19,463 1.24 (1.11-1.37) 
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  BMD 
  Further adjusting for femoral neck BMD at baseline§§ 94/2,020 1.68 (1.08-2.61)|||| 142/4,147 1.22 (1.01-1.47) 
Abbreviations: BMD, bone mineral density; CHS, Cardiovascular Health Study; CI, confidence interval; EPIC, 
European Prospective Investigation of Cancer; FT4, free thyroxine; Health ABC, Health, Aging and Body 
Composition; HUNT, Nord-Trøndelag Health Study; InCHIANTI, Invecchiare in Chianti; MrOS, Osteoporotic 
Fractures in Men Study; No., number; OPUS, Osteoporosis and Ultrasound Study; PROSPER, Prospective Study of 
Pravastatin in the Elderly at Risk; SD, standard deviation; SOF, Study of Osteoporotic Fractures; TSH, thyroid-
stimulating hormone. 
All analyses were adjusted for age (as a continuous variable) and sex. Data for hip fractures were available for 12 
cohorts (all but PROSPER). 
* We present a selected analysis for the TSH category 0.45-0.99mIU/L compared with the reference category (TSH 
3.50-4.99mIU/L). No. are for participants in these both TSH categories only. 
† FT4 was measured in all studies but the SOF and the Health ABC Study (FT4 not measured in participants with 
TSH within reference range). 
‡ Hazard ratios are for TSH 0.45-0.99mIU/L, compared with the reference group 3.50-4.99mIU/L. 
§ Hazard ratios are per one standard deviation increase in FT4. 
||
 Thyroid medication was defined as thyroxine or anti-thyroid medication. 
¶ Thyroid-altering medication included oral corticosteroid, amiodarone, iodine, thyroxine, or anti-thyroid 
medication. 
**
 Anti-fracture medication was defined as bisphosphonate, calcitonin, selective estrogen receptor modulator, or 
parathyroid hormone. 
†† EPIC-Norfolk Study, HUNT Study, InCHIANTI Study, MrOS, OPUS, Rotterdam Study, Sheffield Study, Health 
ABC Study, and SOF (Health ABC Study and SOF only in the TSH analysis). 
‡‡ OPUS. 
§§ Femoral neck BMD at baseline was available in following studies: CHS, MrOS, Rotterdam Study, Sheffield 
Study, OPUS, Health ABC Study. 
||||
 Participants within the TSH category 3.50-4.49mIU/L had lower femoral neck BMD at baseline than participants 
within the TSH category 0.45-1.50mIU/L (mean [SD]: 0.77g/cm2 [0.16] versus 0.79 g/cm2 [0.15], respectively, P = 
0.002), which explains the higher hazard ratio after adjusting for femoral neck BMD at baseline. 
Table 3. Sensitivity and stratified analyses for the risk of any, non-vertebral, and vertebral 
fractures, per one standard deviation increase in free thyroxine 
Any fracture* Non-vertebral fracture† Vertebral fracture‡  
No. of events/ 
participants 
Hazard ratio (95% 
CI) 
No. of 
events/ 
participants 
Hazard ratio 
(95% CI) 
No. of events/ 
participants 
Hazard ratio (95% 
CI) 
Main analysis 1,629/22,977 1.08 (1.02-1.15) 1,273/19,101 1.10 (1.03-1.18) 129/17,711 1.06 (0.86-1.30) 
  SENSITIVITY ANALYSES 
  Medication use 
 Excluding 
participants with 
thyroid 
medication at 
baseline§ 
1,552/22,440   1.09 (1.02-1.16) 1,240/18,697 1.14 (1.06-1.23) 125/17,309 1.08 (0.86-1.37) 
 Excluding 
participants with 
thyroid-altering 
medication at  
baseline|| 
1,537/21,976 1.09 (1.02-1.15) 1,200/18,256 1.11 (1.03-1.19) 125/16,868 1.07 (0.86-1.32) 
 Excluding 
participants with 
anti-fracture 
medication at 
baseline¶ 
1,622/22,927 1.08 (1.02-1.15) 1,263/19,038 1.10 (1.03-1.18) 127/17,666 1.05 (0.85-1.29) 
  Definition of fracture 
  Including only 
studies with 
formal fracture 
1,026/15,805 1.11 (1.02-1.19) 1,111/17,208 1.11 (1.03-1.19) 113/15,806 1.07 (0.86-1.32) 
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16 
adjudication** 
  Including only 
studies with 
most uniform 
definition of 
fracture†† 
1,155/19,728 1.06 (0.99-1.14) 685/14,461 1.08 (0.98-1.19) 65/14,462 1.10 (0.83-1.47) 
  Other  
 Further 
adjusting for 
BMI, smoking 
status, and 
diabetes mellitus
1,591/22,536 1.21 (1.00-1.46) 1,140/17,562 1.09 (1.01-1.18) 126/17,290 1.03 (0.83-1.27) 
 Excluding 
studies with loss 
of follow-up rate 
>5% 
NA NA 1,174/17,981 1.13 (1.04-1.22) NA NA 
  BMD 
  Further 
adjusting for 
lumbar spine 
BMD at 
baseline‡‡ 
NA NA NA NA 39/1,399 0.96 (0.68-1.36) 
  Further 
adjusting for 
whole body 
BMD at 
baseline§§ 
183/1,399 0.89 (0.75-1.04) NA NA NA NA 
  STRATIFIED ANALYSES 
  Stratified for sex  
 Women 1,013/11, 321 1.11 (1.03-1.19) 827/10,075 1.10 (1.01-1.20) 62/8,679 1.12 (0.83-1.51) 
 Men 616/11,656 1.05 (0.95-1.15) 446/9,026 1.08 (0.96-1.22) 67/9,032 1.00 (0.75-1.33) 
P-value for 
interaction 
NA 0.39 NA 0.79 NA 0.61 
  Stratified for age  
 <75 years at 
baseline 
1,041/18,367 1.10 (1.02-1.19) 955/17,144 1.10 (1.02-1.20) 87/15,917 0.96 (0.74-1.25) 
≥75 years at 
baseline 
588/4610 1.06 (0.96-1.16) 318/1,957 1.10 (0.97-1.25) 42/1,794 1.25 (0.88-1.76) 
P-value for 
interaction 
NA 0.47 NA 0.99 NA 0.25 
  Stratified for duration of follow-up  
 <5 years  446/5,920 1.04 (0.93-1.15) 47/888 0.82 (0.59-1.14) 7/888 0.60 (0.26-1.37) 
  ≥5 years  1,183/17,057 1.09 (1.02-1.18) 1,226/18,213 1.10 (1.03-1.18) 122/16,823 1.07 (0.87-1.33) 
P-value for 
interaction 
NA 0.39 NA 0.07 NA 0.18 
Abbreviations: BMD, bone mineral density; BMI, body mass index; CI, confidence interval; EPIC, European 
Prospective Investigation of Cancer; FT4, free thyroxine; Health ABC, Health, Aging and Body Composition; 
InCHIANTI, Invecchiare in Chianti Study; MrOS, Osteoporotic Fractures in Men Study; NA, not appropriate; No., 
number; OPUS, Osteoporosis and Ultrasound Study; PROSPER, Prospective Study of Pravastatin in the Elderly at 
Risk; SD, standard deviation; SOF, Study of Osteoporotic Fractures; TSH, thyroid-stimulating hormone. 
All analyses were adjusted for age (as a continuous variable) and sex; FT4 was measured in all studies but SOF and 
Health ABC Study (FT4 not measured in participants with TSH within the reference range). 
Hazard ratios are per one standard deviation increase in FT4. 
* Data on any fractures were available for 7 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Leiden 85-
Plus Study, PROSPER, Rotterdam Study, Busselton Health Study). 
† Data on non-vertebral fractures were available for 7 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, 
Rotterdam Study, Busselton Health Study, Sheffield Study, OPUS). 
‡ Data on vertebral fractures were available for 5 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, 
Rotterdam Study, Busselton Health Study). Vertebral fracture was defined as a clinical symptomatic dorsal or 
lumbar fracture. 
§ Thyroid medication was defined as thyroxine or anti-thyroid medication. 
||
 Thyroid-altering medication included oral corticosteroid, amiodarone, iodine, thyroxine, or anti-thyroid drug. 
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17 
¶ Anti-fracture medication was defined as bisphosphonate, calcitonin, selective estrogen receptor modulator, or 
parathyroid hormone. 
**
 EPIC-Norfolk Study, InCHIANTI Study, MrOS, OPUS, Rotterdam Study, Sheffield Study. 
†† EPIC-Norfolk Study, InCHIANTI Study, Leiden 85-Plus Study, MrOS, PROSPER. 
‡‡ Lumbar spine BMD was available in MrOS only. 
§§ Whole body BMD was available in MrOS only. 
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1Thyroid function within the reference range and fracture risk: individual participant analysis of prospective cohorts 
Supplemental Data
2Supplemental Table 1. Description of assays used for TSH and FT4 measurement
Study TSH assay TSH reference range (mIU/L) FT4 assay
FT4 reference 
range pmol/L
Busselton Health 
Study
Immulite 2000 chemiluminescent analyzer (Diagnostic 
Products Corporation, Los Angeles, Calif ), FS 
0.02IU/L, CV 7.6%
0.4-4.0
Immulite 2000 chemiluminescent analyzer 
(Diagnostic Products Corporation, Los Angeles, 
Calif ), CV 9.6%
9-23
CHS
Chemiluminescent immunometric assay (LumaTag 
hTSH; Nichols Institute, San Juan Capistrano, 
California), FS 0.008mIU/L
0.1-4.5 Direct monoclonal antibody assay (Amerlex-MAB; Amersham International, Amersham, England)
4.9-22
EPIC-Norfolk Study AutoDelfia time resolved fluoroimmunoassay kits (Wallac, Finland), FS 0.03mIU/L, CV <3.5% 0.4-4.0
AutoDelfia time resolved fluoroimmunoassay kits 
(Wallac, Finland), FS 2.0pmol/L, CV <4.5%
9-20
Health ABC Study
Immunoassay (ACS; ChironDiagnosticsCorp, 
Emeryville,Calif), CV 4.1% at 18.94mIU/L and 3.6% at 
1.26mIU/L
0.1-4.5 Competitive immunoassay (ACS; ChironDiagnostics Corp)
10.3-23.2
HUNT Study DELFIA hTSH Ultra (Wallac Oy, Turku, Finland), FS 0.03 mIU/L, VC 5% 0.5-3.5 DELFIA FT4, CV <7%*
8-20
InCHIANTI Study
Chemiluminescent Immunoassay (Vitros Reagent, 
Ortho-Clinical Diagnostics, Johnson & Johnson Medical 
Section, Milan, Italy), FS 0.003mIU/L, VC <5.4%
0.46-4.68
Chemiluminescent Immunoassay (Vitros Reagent, 
Ortho-Clinical Diagnostics, Johnson & Johnson 
Medical Section, Milan, Italy), FS 0.39pmol/L, CV 
<5.3%
9.9-28.2
Leiden 85-Plus Study
Elecsys 2010 system (Hitachi, Tokyo, Japan) with an 
electrochemiluminescence technique (Boehringer,
Mannheim, Germany), VC 5-11%
0.3-4.8
Elecsys 2010 system (Hitachi, Tokyo, Japan) with 
an electrochemiluminescence technique 
(Boehringer, Mannheim, Germany), VC 5-8%
13-23
MrOS ADVIA Centaur (Siemens Diagnostics, Deerfield, IL, USA) 0.55-4.78
Competitive immunoassay (Siemens Diagnostics), 
CV 4.1%
9.0-23.8
OPUS
Single automated analyzer using the ARCHITECT 
System (Abbott ARCHITECT i2000; Abbott 
Laboratories, Maidenhead, UK), CV<10.4%
0.13-3.48
single automated analyzer using the ARCHITECT 
System (Abbott ARCHITECT i2000; Abbott 
Laboratories, Maidenhead, UK), CV<10.4%
9.15-16.99
PROSPER Three different immunoassays, FS 0.05 mIU/L, CV <5% 0.45-4.5
Three different immunoassays, FS 0.05 mIU/L, CV 
<5%
12-18**
Rotterdam Study TSH Lumitest (Henning currently Brahms, Berlin, Germany) 0.4-4.0
Chemiluminescence assay (Vitros, ECI 
Immunodiagnostic System, Ortho-Clinical 
Diagnostics, Amersham, UK)
11-25
Sheffield Study
High-sensitivity immunoradiometric assay with reagents 
supplied by NETRIA (St. Bartholomew’s Hospital, 
London, UK), CV 8.0%
One step labelled antibody assay (Amerlex MAB, 
Lifescreen Ltd, Watford, UK), CV 4.8%
SOF Chemiluminescent assay (Endocrine Science, Calabasas, California), FS 0.05mIU/L, CV<6.3% 0.5-5.5 NA
NA
Abbreviations: CHS, Cardiovascular Health Study; CV, coefficient of variation; EPIC, European Prospective Investigation of Cancer; FS, functional sensitivity; FT4, free thyroxine; Health ABC, Health, Aging and 
Body Composition; HUNT, Nord-Trøndelag Health; InCHIANTI, Invecchiare in Chianti; MrOS, Osteoporotic Fractures in Men Study; NA, not appropriate; OPUS, Osteoporosis and Ultrasound Study; PROSPER, 
Prospective Study of Pravastatin in the Elderly at Risk; SOF, Study of Osteoporotic Fractures; TSH, thyroid-stimulating hormone.
Functional sensitivity was defined as the concentration at which the interassay CV is ≥20%.
* In the HUNT Study, FT4 was measured only if TSH was >4.0mIU/L or if the participant had known thyroid disease.
** Narrowed range among 3 different assays used for measurement.
3Supplemental Table 2. Definition of fractures in each study
Study Hip fracture Any fracture Non-vertebral fracture Vertebral fracture
Busselton Health Study ICD10: S72.0-1
Non-vertebral or vertebral 
fracture 
(first event)
Including: ICD9: 807-829. 
Excluding: skull/face 
(ICD9: 800-804)
Clinically diagnosed; cervical (ICD10: 
S12), thoracic (ICD10: S22) or lumbar 
vertebrae (ICD10: S32), vertebrae of 
unknown location (ICD10: T08)
CHS
ICD9: 820.0-820.9 for inpatients, plus 
CPT procedure code on fracture 
treatment for outpatients
NA NA NA
EPIC-Norfolk Study ICD10: S72.0-2
Non-vertebral or vertebral 
fracture
(first event)
Excluding skull/face, ankle, 
fingers, toes
Clinically diagnosed; thoracic (ICD10: 
S22), lumbar vertebrae (ICD10: S32), 
vertebrae of unknown location (ICD10: 
T08)
Health ABC Study Femoral neck, intertrochanteric, proximal femur
Non-vertebral or vertebral 
fracture 
(first event)
Excluding ankle, fingers, 
toes
Clinically diagnosed; thoracic or lumbar 
vertebrae 
HUNT Study
ICD9: 820.0-820.9, SIFF-95 procedure 
codes;
ICD10: S72.0-2, S72.9, NCSP codes
NA NA NA
InCHIANTI Study
ICD9: 820.0-820.9 for inpatients, plus 
CPT procedure code on fracture 
treatment for outpatients
Non-vertebral or vertebral 
fracture 
(first event)
Excluding skull/face, ankle, 
fingers, toes
Clinically diagnosed; thoracic (ICD9: 
805.2-5) or lumbar vertebrae (ICD9: 
806.2-5) 
Leiden 85-Plus Study Any hip fracture Any fracture NA NA
MrOS Femoral neck, intertrochanteric, subtrochanteric
Non-vertebral or vertebral 
fracture 
(first event)
Excluding skull/face, ankle, 
fingers, toes
Clinically diagnosed; thoracic or lumbar 
vertebrae 
OPUS Any low-traumatic hip fracture NA Any low-traumatic non-vertebral fracture NA
PROSPER NA Any fracture NA NA
Rotterdam Study Any hip fracture
Non-vertebral or vertebral 
fracture 
(first event)
Excluding skull, ankle/foot, 
fingers/and/wrist
Any clinically diagnosed vertebral 
fracture
Sheffield Study Any hip fracture NA Any non-vertebral fracture NA
SOF Any hip fracture, excluding severe  traumatic fracture Any fracture
Any non-vertebral fracture, 
excluding severe traumatic 
fracture
Any clinically diagnosed vertebral 
fracture, excluding severe traumatic 
fracture
Abbreviations: CHS, Cardiovascular Health Study; CPT; Current Procedural Terminology; EPIC, European Prospective Investigation of Cancer; GP, general practitioner; Health ABC, Health, Aging and Body 
Composition; HUNT, Nord-Trøndelag Health; ICD, international classification of disease; InCHIANTI, Invecchiare in Chianti; MrOS, Osteoporotic Fractures in Men Study; NA, not appropriate; OPUS, Osteoporosis 
and Ultrasound Study; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; SOF, Study of Osteoporotic Fractures.
4Supplemental Table 3. Study quality assessment
Study Design Setting Ascertainment of exposure
Covariates available 
for adjustment
Assessment of fractures Adjudication 
blinded to 
thyroid 
function
Median 
(IQR) 
length of 
follow-up
Loss to 
follow-up
Fractures 
data 
publishedaMethod used Formal adjudication
Busselton
Health Study
Prospective 
cohort study
Population-
based study
Third generation 
TSH assay
Age, sex, BMI,
smoking status, 
diabetes; thyroid and 
anti-osteoporotic 
medication
ICD9 and ICD10 
coded diagnoses in 
hospital discharge 
records
No NA 20.0(17.6-20.0) 5% No
CHS Prospective cohort study
Population-
based study
Third generation 
TSH assay
Age, sex, BMI, 
smoking status, 
diabetes; thyroid, 
thyroid-altering and 
anti-osteoporotic 
medication
Interview and 
hospital records 
reviewed by experts
No NA 13.0(7.6-19.0) 0% Yes
EPIC-Norfolk 
Study
Prospective 
cohort study
Population-
based study
Third generation 
TSH assay
Age, sex, BMI,
smoking status, 
diabetes; thyroid and 
thyroid-altering 
medication
Hospital discharge 
coding by data 
linkage with NHS 
central register
Yes Yes 12.4(11.7-13.3) 1.3% Yes
Health ABC 
Study
Prospective 
cohort
tstudy
Population-
based study
Third generation 
TSH assay
Age, sex, BMI, 
smoking status, 
diabetes; thyroid, 
thyroid-alterating and 
anti-osteoporotic 
medication
Interview, hospital 
records and other 
documents reviewed 
by clinicians
Yes Yes 12.7(8.0-13.2) <5% Yes
HUNT Study Prospective cohort study
Population-
based study
Third generation 
TSH assay
Age, sex, BMI, 
smoking status, 
diabetes; thyroid and 
thyroid-altering 
medication
Hospital and 
radiology records 
reviewed by 
physicians, health 
secretaries and 
nurses
Yes Yes 12.2(11.6-12.8) <5% Yes
InCHIANTI 
Study
Prospective 
cohort study
Population-
based study
Third generation 
TSH assay
Age, sex, BMI, 
smoking status, 
diabetes; thyroid, 
thyroid-altering and 
anti-osteoporotic 
medication
Hospital records 
and other 
documents
Yes Yes 9.1(7.8-9.3) <5% No
Leiden 85-
Plus Study
Prospective 
cohort study
Population-
based study
Third generation 
TSH assay
Age, sex, BMI, 
smoking status, 
diabetes; thyroid, 
thyroid-alterating and 
anti-osteoporotic 
medication
Annual interview of 
treating GP or 
nursing home 
physician and 
review of their 
medical records
No NA 4.8(2.2-8.1) <4% Yes
5Study Design Setting Ascertainment of exposure
Covariates available 
for adjustment
Assessment of fractures Adjudication blinded to 
thyroid 
function
Median 
(IQR) 
length of 
follow-up
Loss to 
follow-up
Fractures 
data 
published*Method used Formal adjudication
MrOS
Random 
sample of a 
prospective 
cohort study
Sample of 
community-
dwelling 
volunteers
Third generation 
TSH assay
Age, sex, BMI, 
smoking status, 
diabetes; thyroid, 
thyroid-alterating and 
anti-osteoporotic 
medication
Interviewed 
reported fractures. 
Central adjudication 
by physician 
through radiology 
reports or X-rays
Yes Yes 11.1(8.1-11.8) 2% Yes
OPUS Prospective cohort study
Population-
based study
Third generation 
TSH assay
Age, sex, BMI, 
smoking status, 
diabetes; thyroid, 
thyroid-altering and 
anti-osteoporotic 
medication
Interview after 6 
years follow-up, 
validated by 
medical records and 
imaging reviewed 
by radiologist
Yes Yes 6.0(5.8-6.3) 40% Yes
PROSPER Prospective cohort study
Population-
based study
Third generation 
TSH assay
Age, sex, BMI, 
smoking status, 
diabetes; thyroid and 
thyroid-altering 
medication
Fractures 
documented as 
adverse events
No NA 3.3(3.0-3.5) <1% No
Rotterdam 
Study
Prospective 
cohort study
Population-
based study
Third generation 
TSH assay
Age, sex, BMI, 
smoking status, 
diabetes; thyroid 
medication
GP and hospital 
registry records, 
reviewed by 
independent 
medical experts
Yes Yes 15.2(10.4-16.2) <1% Yes
Sheffield 
Study
Prospective 
cohort study
Population-
based study
Third generation 
TSH assay
Age, sex, BMI, 
smoking status, 
diabetes; thyroid 
medication
GP records and 
interviews, if 
confirmed by 
radiology or 
orthopedic report
Yes Yes 10.0(2.8-10.1) 2% Yes
SOF Prospective cohort study
Sample of 
community-
dwelling 
volunteers
Third generation 
TSH assay
Age, sex, BMI, 
smoking status, 
diabetes; thyroid, 
thyroid-altering and 
anti-osteoporotic 
medication
Mail interview, with 
confirmation by X-
rays or written 
report review by 
radiologist
Yes Yes 14.3(9.8-19.8) 5% Yes
Abbreviations: BMI, body mass index; CHS, Cardiovascular Health Study; EPIC, European Prospective Investigation of Cancer; GP, general practitioner; Health ABC, Health, Aging and Body Composition; HUNT, Nord-Trøndelag 
Health; ICD, international classification of disease; InCHIANTI, Invecchiare in Chianti Study; IQR, interquartile range; MrOS, Osteoporotic Fractures in Men Study; OPUS, Osteoporosis and Ultrasound Study; PROSPER, Prospective 
Study of Pravastatin in the Elderly at Risk; SOF, Study of Osteoporotic Fractures; TSH, thyroid-stimulating hormone.
* Four cohorts had not published their fractures data in a separate manuscript previously.
6Supplemental Table 4. Analysis stratified by publication status of fractures data
Analysis by thyroid-stimulating hormone categories
Hip fracture* Any fracture† Non-vertebral fracture‡ Vertebral fracture§
No. of events/ 
participants
Hazard ratio
(95% CI) 
No. of events/ 
participants
Hazard ratio
(95% CI) 
No. of events/ 
participants
Hazard ratio
(95% CI) 
No. of events/ 
participants
Hazard ratio
(95% CI) 
Main analysis 610/13,390 1.25 (1.05-1.49) 561/5,587 1.00 (0.83-1.19) 504/5,013 1.04 (0.85-1.26) 60/4,854 1.46 (0.82-2.61)
Studies with published 
fractures studies 572/12,460 1.35 (1.13-1.61) 387/4,097 1.16 (0.93-1.43) 423/4,643 1.27 (1.03-1.57) 53/3,977 1.44 (0.79-2.62)
Studies with unpublished 
fractures data|| 33/865 0.44 (0.21-0.90) 172/2,039 0.70 (0.50-0.96) 79/862 0.54 (0.33-0.91) 7/858 1.17 (0.14-9.88)
P-value for interaction NA 0.0001 NA 0.17 NA 0.12 NA 0.84
Analysis by one standard deviation increase in free thyroxine¶
Hip fracture** Any fracture†† Non-vertebral fracture‡‡ Vertebral fracture§§
No. of events/ 
participants
Hazard ratio
(95% CI) 
No. of events/ 
participants
Hazard ratio
(95% CI) 
No. of events/ 
participants
Hazard ratio
(95% CI) 
No. of events/ 
participants
Hazard ratio
(95% CI) 
Main analysis 542/20,633 1.24 (1.12-1.37) 1,629/22,977 1.08 (1.02-1.15) 1,273/19,101 1.10 (1.03-1.18) 129/17,711 1.06 (0.86-1.30)
Studies with published  
fractures studies 453/17,663 1.25 (1.12-1.40) 1,003/15,192 1.09 (1.01-1.18) 1,031/16,143 1.12 (1.03-1.20) 103/14,741 1.09 (0.67-1.76)
Studies with unpublished 
fractures datae 89/2,970 1.16 (0.90-1.89) 626/7,785 1.07 (0.97-1.17) 242/2,958 1.03 (0.87-1.20) 26/2,970 1.05 (0.84-1.31)
P-value for interaction NA 0.59 NA 0.70 NA 0.35 NA 0.89
Abbreviations: CHS, Cardiovascular Health Study; CI, confidence interval; EPIC, European Prospective Investigation of Cancer; Health ABC, Health, Aging and Body Composition; InCHIANTI, Invecchiare in Chianti; 
MrOS, Osteoporotic Fractures in Men Study; OPUS, Osteoporosis and Ultrasound Study; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; SOF, Study of Osteoporotic Fractures; TSH, thyroid-stimulating 
hormone.FT4, free thyroxine; No., number.
All analyses were adjusted for age (as a continuous variable) and sex.
* Data on hip fractures were available for 12 studies (all but PROSPER).
† Data on any fractures were available for 9 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Leiden 85-Plus Study, PROSPER, Rotterdam Study, Busselton Health Study, SOF, Health ABC Study).
‡Data on non-vertebral fractures were available for 9 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Rotterdam Study, Busselton Health Study, Sheffield Study, OPUS, SOF, Health ABC Study).
§Data on vertebral fracture were available for 7 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Rotterdam Study, Busselton Health Study, SOF, Health ABC Study). Vertebral fracture was defined as a clinical 
symptomatic dorsal or lumbar fracture.
|| Busselton Health Study, and InCHIANTI Study did not previously publish hip fracture data associated with thyroid function in a separate article.
¶FT4was measured in all studies but SOF and Health ABC Study (FT4not measured in participants with TSH within normal range). 
**Data on hip fracture were available for 10 studies with measured FT4 (all but PROSPER).
††Data on any fracture were available for 7 studies with measured FT4 (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Leiden 85-Plus Study, PROSPER, Rotterdam Study, Busselton Health Study).
‡‡ Data on non-vertebral fracture were available for 7 studies with measured FT4 (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Rotterdam Study, Busselton Health Study, Sheffield Study, OPUS).
§§ Data on vertebral fracture were available for 5 studies with measured FT4 (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Rotterdam Study, Busselton Health Study). Vertebral fracture was defined as a clinical 
symptomatic dorsal or lumbar fracture.
7Supplemental Table 5. Risk of any, non-vertebral, and vertebral fractures according to thyroid-stimulating 
hormone categories
TSH level (mIU/L)
Any fracture* Non-vertebral fracture† Vertebral fracture‡
No. of events/ 
participants
Hazard ratio
(95% CI)
No. of events/ 
participants
Hazard ratio
(95% CI)
No. of events/ 
participants
Hazard ratio
(95% CI)
3.50-4.49
2.50-3.49
1.50-2.49
1.00-1.49
0.45-0.99
179/1,769
376/4,096
841/9,847
555/6,105
382/4,379
1 (Reference)
0.98 (0.82-1.17)
1.01 (0.86-1.19)
1.07 (0.90-1.27)
1.00 (0.83-1.19)
140/1,396
280/3,301
650/8,033
440/5,165
364/4,121
1 (Reference)
0.91 (0.74-1.12)
0.97 (0.81-1.17)
1.02 (0.84-1.24)
1.04 (0.85-1.26)
16/1,353
48/3,194
99/7,752
56/4,818
44/3,501
1 (Reference)
1.40 (0.80-2.47)
1.48 (0.87-2.50)
1.35 (0.78-2.37)
1.46 (0.82-2.61)
P-value  for trend NA 0.56 NA 0.19 NA 0.43
Abbreviations: CI, confidence interval; Health ABC, Health, Aging and Body Composition; No., number; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; SOF, 
Study of Osteoporotic Fractures; TSH, thyroid-stimulating hormone.
All analyses were adjusted for age (as a continuous variable) and for sex.
* Data on any fractures were available for 9 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Leiden 85-Plus Study, PROSPER, Rotterdam Study, Busselton Health Study, 
SOF, Health ABC Study).
† Data on non-vertebral fractures were available for 9 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Rotterdam Study, Busselton Health Study, Sheffield Study, OPUS, 
SOF, Health ABC Study).
‡ Data on vertebral fractures were available for 7 studies (MrOS, EPIC-Norfolk Study, InCHIANTI Study, Rotterdam Study, Busselton Health Study, SOF, Health ABC Study). 
Vertebral fracture was defined as a clinical symptomatic dorsal or lumbar fracture.
8Supplemental Figure 1. Flow diagram of the studies assessed for inclusion
Abbreviations: IPD, individual participants data; TSH, thyroid-stimulating hormone.
9Supplemental Figure 2. Risk of hip fracture in participants with thyroid-stimulating hormone 0.45-
1.49mIU/L, compared to the reference group with thyroid-stimulating hormone 3.50-4.49mIU/L, 
stratified by sex, age, and duration of follow-up
Abbreviations: CI, confidence interval; HR, hazard ratio; No, number; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; TSH, thyroid-stimulating 
hormone.
We present a selected analysis for the TSH categories 0.45-0.99mIU/L and 3.50-4.99mIU/L. Hazard ratios are for TSH 0.45-0.99mIU/L, compared with the reference group 
3.50-4.99mIU/L. The analysis stratified by sex was adjusted for age. All other analyses were adjusted for age (as a continuous variable) and sex.
Data on hip fractures were available for 12 studies (all except PROSPER).
